NSE: BIOCON | BSE: 532523

Strong Performer, Getting Expensive

Download real time

390.30 -0.10 (-0.03%)

34.12% Gain from 52W Low

129.3K NSE+BSE Volume

NSE 30 Dec, 2025 9:23 AM (IST)

52,181.7

Market Cap

Market Leader

Beta 1Year

Very High Volatility

Biocon Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for BIOCON, BSE:532523 Biocon Ltd.

Search Inside the pdf :

Biocon Ltd.

10 Dec 2025

390.30

-0.03%

Biocon Ltd.

Sell: Biocon Ltd.

Recommendation Target

ICICI Direct

announced to acquire entire minority shareholder stake of 23.3% in Biocon Biologics held by Viatris (Mylan Inc.), Serum Institute, True North and Tata Capital for US$ 1.173 billion, making it a wholly-owned subsidiary and valuing BBL at US$ 5.5 billion. Biocon will issue its shares worth US$ 773 million and make a cash payment to Viatris for the balance US$ 400 million. Cash payment to be paid by bridge / interim funding and a...

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

08 Dec 2025

390.30

-0.03%

Integration to bring scale and clarity

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) is fully integrating Biocon Biologics (BBL) by acquiring the remaining stake of 23.3%. In addition to the share swap, BIOS is raising additional capital through a QIP of up to INR45b, subject to shareholder approval, for the cash component payable to Viatris.

Biocon Ltd. is trading above its 200 day SMA of 360.3

Biocon Ltd.

29 Nov 2025, 12:00AM

390.30

-0.03%

Pick of the Week:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

BUY with a target price of Rs 440, implying an upside of ~10% from the CMP.

Biocon Ltd. is trading below its 30 day SMA of 395.5

Biocon Ltd.

14 Nov 2025

390.30

-0.03%

Launches boost growth; profitability improvement tepid

Sell: Biocon Ltd.

Target

ICICI Securities Limited

Biocon’s Q2FY26 revenue growth of 19.6% YoY was driven by recent launches like bUstekinumab, bAspart, bBevacizumab and bAflibercept, and the launch of generic liraglutide.

Biocon Ltd. is trading above its 200 day SMA of 360.3

Biocon Ltd.

13 Nov 2025

390.30

-0.03%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

we maintain a BUY rating on the stock.

Biocon Ltd. has an average target of 376.40 from 5 brokers.

Biocon Ltd.

12 Nov 2025

390.30

-0.03%

Operationally in-line 2Q; healthy growth in core business

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) delivered in-line revenue/EBITDA for 2QFY26. PAT for the quarter was better than expected, driven by lower minority interest for the quarter.

Biocon Ltd. is trading above its 200 day SMA of 360.3

Biocon Ltd.

03 Oct 2025

390.30

-0.03%

BIOCON LTD

Sell: Biocon Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues. In Q1FY26, Biocon's consolidated revenue grew 14.8% YoY to Rs. 3,942cr, driven...

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

11 Aug 2025

390.30

-0.03%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

09 Aug 2025

390.30

-0.03%

Margin pressure persists

Sell: Biocon Ltd.

Target

ICICI Securities Limited

Biocon’s Q1FY26 performance was marred by operating cost of new facilities for generic division and lower-thananticipated margins in biologics division.

Number of FII/FPI investors decreased from 333 to 308 in Sep 2025 qtr

Biocon Ltd.

08 Aug 2025

390.30

-0.03%

Temporary headwinds in generics weigh on 1Q

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) reported lower-than-expected financial performance in 1QFY26, affected mainly by a sharp reduction in generics sales and increased opex related to new facilities.

Biocon Ltd. is trading above its 200 day SMA of 360.3

Is Biocon Ltd. worth buying?

734 Votes:

Buy 74.8%

Sell 16.35%

Hold 8.86%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf